#United States #Boston #Complete Genomics #SOPHiA GENETICS #DNBSEQ-T1+

Complete Genomics and SOPHiA GENETICS Unite for Enhanced Genomic Testing at AMP 2025

In a groundbreaking move towards innovative cancer care, Complete Genomics and SOPHiA GENETICS have announced their collaboration to integrate MSK-IMPACT® and MSK-ACCESS® assays with their DNBSEQ-T1+ sequencing platform. This partnership was unveiled during the prestigious Association for Molecular Pathology (AMP) Annual Meeting held in Boston from November 11-15, 2025.

A New Era for Precision Oncology

Complete Genomics, a leader in genomic sequencing, has joined forces with SOPHiA GENETICS, a pioneer in AI-driven precision medicine, to enhance the accessibility of precision oncology testing. By leveraging their advanced technologies, the companies aim to provide superior liquid biopsy and solid tumor applications on a global scale.

According to Rob Tarbox, Vice President of Product and Marketing at Complete Genomics, this integration forms a robust solution for laboratories aiming to scale high-quality genomic profiling for cancer. He emphasized the strengths of merging SOPHiA GENETICS’ rigorously validated assays with Complete Genomics’ cutting-edge sequencing technology, thereby providing decentralized labs with timely, accurate, and affordable insights.

Ross Muken, President of SOPHiA GENETICS, echoed this commitment by stating that the collaboration underscores their mission to foster access to data-driven medicine, enabling more laboratories internationally to adopt precision oncology through effective genomic solutions.

Advanced Technology in Action

The collaboration will make use of the DNBSEQ-T1+ platform, which employs proprietary DNBSEQ technology, showcasing impressive Q40-level accuracy. This platform permits an optimized throughput ranging from 500 million to 2 billion reads per flow cell. Notably, each flow cell can operate independently, with an efficient turnaround time of 24 hours for paired-end 150bp sequencing. Such flexibility allows laboratories to test up to 60 tumor-normal sample pairs for tissue or 16 for liquid biopsies in maximum throughput scenarios.

Moreover, the SOPHiA DDM™ platform will play a crucial role by providing analytics capabilities that standardize and interpret complex healthcare data. The collaboration's joint evaluations of MSK-IMPACT® and MSK-ACCESS® demonstrated high consistency in variant calls and allele frequencies, outperforming other sequencing systems with lowered background noise and improved compatibility with existing workflows.

Benefiting Clinical Laboratories and Cancer Research

This collaborative effort is designed to offer clinical laboratories, cancer centers, and pharmaceutical developers a cost-efficient and high-performance approach to realizing comprehensive genomic profiling necessary for precision oncology research. With such advancements, the future of cancer diagnostics appears promising, promoting better patient care and paving the way for innovative treatments.

Professionals attending the AMP 2025 conference are encouraged to visit the Complete Genomics and SOPHiA GENETICS booths to explore firsthand the potential of these groundbreaking technologies.

For further information about this collaboration, you can explore the respective company websites at Complete Genomics and SOPHiA GENETICS. Together, they are making strides in transforming cancer treatment through advanced genomic solutions.